BLFS on Nasdaq
BIOLIFE SOLUTIONS INC
American electromedical and electrotherapeutic apparatus company2
In its 2026 annual report the company says: “We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy industry. Our products are used in basic and applied research and commercial manufacturing of biologic-based therapies. We currently operate as one bioproduction products and services business which supports several steps in the biologic material manufacturing and delivery process.”5 It is headquartered in Bothell, United States.2 Its shares trade on Nasdaq under the symbol BLFS.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with ViewRay, VASO Corp or Ceribell, Inc., or pick any stock.
- TickerBLFS on Nasdaq2
- IndustryElectromedical & Electrotherapeutic Apparatus2
- HeadquartersBothell, United States2
- Incorporated inDE3
- Business address3303 Monte Villa Parkway, Suite 310, Bothell, Wa 980213
- Filer categoryLarge accelerated filer3
- Legal formCorporation2
- LEI549300G2IVCMC2TJDW722
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o NATIONAL REGISTERED AGENTS, INC., 1209 ORANGE STREET, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 28720602
See how the biggest companies compare on our leaderboards
The following discussion of our business contains forward-looking statements that involve risks and uncertainties (see the section entitled “ Forward-Looking Statements ” herein). Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including those factors set forth under “ Risk Factors ” and elsewhere in this Form 10-K.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
64.6%Gross margin6
-17.3%Operating margin6
-4.8%Net margin6
28.9%Revenue growth, 20256
-1.2%Return on equity6
0.00×Debt to equity6
$10.6MFree cash flow6
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue35¢$34.1M
- Research and development8¢$7.6M
- Other costs57¢$54.5M
- Income tax0¢$49.0K
Out of $96.2M in revenue.6 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending47¢$9.5M
- Kept or used elsewhere53¢$10.6M
Out of $20.1M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M |
| Cost of revenue | $34.1M | $24.6M | $26.7M |
| Gross profit | $62.1M | $50.1M | $41.3M |
| General and administrative | $45.5M | $40.6M | $42.8M |
| Sales and marketing | $9.8M | $8.9M | $11.4M |
| Research and development | $7.6M | $4.8M | $5.5M |
| IPR&D expense | $15.5M | $0 | $0 |
| Intangible asset amortization | $263.0K | $263.0K | $1.0M |
| Change in fair value of contingent consideration | $0 | $0 | -$2.2M |
| Total operating expenses | $78.7M | $54.6M | $58.5M |
| Operating loss | -$16.6M | -$4.5M | -$17.2M |
| Interest income (expense), net | $2.7M | -$766.0K | -$1.4M |
| Other income | $1.8M | $494.0K | $1.3M |
| Change in fair value of investments | $0 | -$4.1M | $0 |
| Gain on settlement of Global Cooling escrow | $0 | $0 | $5.1M |
| Total other income (expense), net | $4.5M | -$4.3M | $5.0M |
| Loss from continuing operations before income tax expense (benefit) | -$12.1M | -$8.8M | -$12.2M |
| Income tax expense (benefit) | $49.0K | -$38.0K | -$64.0K |
| Loss from continuing operations | -$12.1M | -$8.8M | -$12.2M |
| Income (loss) from discontinued operations before income tax expense | $7.5M | -$11.3M | -$55.6M |
| Income tax expense | $0 | $132.0K | $233.0K |
| Income (loss) from discontinued operations | $7.5M | -$11.4M | -$55.8M |
| Net loss | -$4.6M | -$20.2M | -$68.0M |
| Continuing operations (in dollars per share) | -$0 | -$0 | -$0 |
| Discontinuing operations (in dollars per share) | $0 | -$0 | -$1 |
| Net loss (in dollars per share) | -$0.09 | -$0.44 | -$1.55 |
| Continuing operations (in dollars per share) | -$0 | -$0 | -$0 |
| Discontinuing operations (in dollars per share) | $0 | -$0 | -$1 |
| Net loss (in dollars per share) | -$0.10 | -$0.44 | -$1.55 |
| Basic (in shares) | 47.8M shares | 46.1M shares | 43.7M shares |
| Diluted (in shares) | 48.6M shares | 46.1M shares | 43.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $33.0M | $91.5M | ||
| Available-for-sale securities, current portion | $55.9M | $9.2M | ||
| Accounts receivable, trade, net of allowance for credit losses of $22 and $152 as of December 31, 2025 and December 31, 2024, respectively | $8.0M | $8.5M | ||
| Inventories | $30.2M | $29.0M | ||
| Prepaid expenses and other current assets | $9.5M | $6.0M | ||
| Current assets, discontinued operations | $0 | $4.6M | ||
| Total current assets | $136.6M | $148.8M | ||
| Property and equipment, net | $14.7M | $6.0M | ||
| Operating lease right-of-use assets, net | $7.5M | $10.6M | ||
| Other assets | $3.0M | $373.0K | ||
| Available-for-sale securities, long term | $31.2M | $4.6M | ||
| Equity investments | $0 | $995.0K | ||
| Intangible assets, net | $4.3M | $5.6M | ||
| Goodwill | $208.6M | $208.6M | ||
| Long-term assets, discontinued operations | $0 | $14.1M | ||
| Total assets | $405.9M | $399.5M | ||
| Accounts payable | $1.5M | $3.4M | ||
| Accrued expenses and other current liabilities | $12.0M | $12.1M | ||
| Sales taxes payable | $2.3M | $4.2M | ||
| Lease liabilities, operating, current portion | $2.2M | $1.5M | ||
| Debt, current portion | $5.0M | $10.9M | ||
| Current liabilities, discontinued operations | $0 | $616.0K | ||
| Total current liabilities | $23.0M | $32.7M | ||
| Lease liabilities, operating, long-term | $10.7M | $12.6M | ||
| Debt, long-term | $0 | $5.0M | ||
| Deferred tax liabilities | $189.0K | $124.0K | ||
| Other long-term liabilities | $171.0K | $0 | ||
| Long-term liabilities, discontinued operations | $0 | $78.0K | ||
| Total liabilities | $34.0M | $50.6M | ||
| Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 150,000,000 shares authorized, 48,198,928 and 46,906,765 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $48.0K | $47.0K | ||
| Additional paid-in capital | $711.4M | $683.9M | ||
| Accumulated other comprehensive loss, net of taxes | $132.0K | $24.0K | ||
| Accumulated deficit | -$339.7M | -$335.1M | ||
| Total shareholders equity | $371.9M | $348.9M | $337.7M | $364.2M |
| Total liabilities and shareholders equity | $405.9M | $399.5M | ||
| Allowance for doubtful accounts | $22.0K | $152.0K | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 1.0M shares | 1.0M shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 150.0M shares | 150.0M shares | ||
| Common stock, issued (in shares) | 48.2M shares | 46.9M shares | ||
| Common stock, outstanding (in shares) | 48.2M shares | 46.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $33.0M | $91.5M | ||
| Available-for-sale securities, current portion | $55.9M | $9.2M | ||
| Accounts receivable, trade, net of allowance for credit losses of $22 and $152 as of December 31, 2025 and December 31, 2024, respectively | $8.0M | $8.5M | ||
| Inventories | $30.2M | $29.0M | ||
| Prepaid expenses and other current assets | $9.5M | $6.0M | ||
| Current assets, discontinued operations | $0 | $4.6M | ||
| Total current assets | $136.6M | $148.8M | ||
| Property and equipment, net | $14.7M | $6.0M | ||
| Operating lease right-of-use assets, net | $7.5M | $10.6M | ||
| Other assets | $3.0M | $373.0K | ||
| Available-for-sale securities, long term | $31.2M | $4.6M | ||
| Equity investments | $0 | $995.0K | ||
| Intangible assets, net | $4.3M | $5.6M | ||
| Goodwill | $208.6M | $208.6M | ||
| Long-term assets, discontinued operations | $0 | $14.1M | ||
| Total assets | $405.9M | $399.5M | ||
| Accounts payable | $1.5M | $3.4M | ||
| Accrued expenses and other current liabilities | $12.0M | $12.1M | ||
| Sales taxes payable | $2.3M | $4.2M | ||
| Lease liabilities, operating, current portion | $2.2M | $1.5M | ||
| Debt, current portion | $5.0M | $10.9M | ||
| Current liabilities, discontinued operations | $0 | $616.0K | ||
| Total current liabilities | $23.0M | $32.7M | ||
| Lease liabilities, operating, long-term | $10.7M | $12.6M | ||
| Debt, long-term | $0 | $5.0M | ||
| Deferred tax liabilities | $189.0K | $124.0K | ||
| Other long-term liabilities | $171.0K | $0 | ||
| Long-term liabilities, discontinued operations | $0 | $78.0K | ||
| Total liabilities | $34.0M | $50.6M | ||
| Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $0 | $0 | ||
| Common stock, $0.001 par value; 150,000,000 shares authorized, 48,198,928 and 46,906,765 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $48.0K | $47.0K | ||
| Additional paid-in capital | $711.4M | $683.9M | ||
| Accumulated other comprehensive loss, net of taxes | $132.0K | $24.0K | ||
| Accumulated deficit | -$339.7M | -$335.1M | ||
| Total shareholders equity | $371.9M | $348.9M | $337.7M | $364.2M |
| Total liabilities and shareholders equity | $405.9M | $399.5M | ||
| Allowance for doubtful accounts | $22.0K | $152.0K | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 1.0M shares | 1.0M shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 150.0M shares | 150.0M shares | ||
| Common stock, issued (in shares) | 48.2M shares | 46.9M shares | ||
| Common stock, outstanding (in shares) | 48.2M shares | 46.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$4.6M | -$20.2M | -$68.0M |
| Impairment of intangible assets | $0 | $0 | $5.8M |
| Impairment of long-lived assets | $0 | $0 | $9.7M |
| Gain on settlement of Global Cooling escrow | $0 | $0 | -$5.1M |
| Depreciation | $2.3M | $5.2M | $7.1M |
| Amortization of intangible assets | $2.4M | $3.5M | $5.2M |
| Amortization of loan costs | $0 | $0 | $13.0K |
| Stock-based compensation | $23.0M | $30.9M | $33.2M |
| Non-cash lease expense | $1.9M | $424.0K | $404.0K |
| Deferred income tax expense (benefit) | $65.0K | -$64.0K | -$62.0K |
| Change in fair value of contingent consideration | $0 | $0 | -$2.2M |
| Change in fair value of equity investment and other | -$983.0K | $4.1M | $0 |
| Accretion of investments | -$736.0K | -$474.0K | -$1.3M |
| Loss on disposal of assets held for rent, net | $510.0K | $567.0K | $594.0K |
| Loss on disposal of property and equipment, net | $11.0K | $154.0K | $633.0K |
| IPR&D expense | $15.5M | $0 | $0 |
| Net gain on disposal of subsidiaries | -$10.3M | -$15.9M | $0 |
| Accounts receivable, trade, net | $264.0K | -$2.9M | $15.4M |
| Inventories | -$1.3M | $781.0K | -$8.6M |
| Prepaid expenses and other current assets | -$3.0M | -$2.4M | $137.0K |
| Accounts payable | -$2.1M | $26.0K | -$8.4M |
| Accrued expenses and other current liabilities | -$1.1M | $6.5M | $2.0M |
| Sales taxes payable | -$1.9M | -$973.0K | $1.3M |
| Warranty liability | $5.0K | -$528.0K | -$454.0K |
| Other | $264.0K | -$258.0K | $97.0K |
| Net cash provided by (used in) operating activities | $20.1M | $8.4M | -$12.5M |
| Purchases of property and equipment | -$9.5M | -$3.2M | -$6.4M |
| Purchases of assets held for rent | -$886.0K | -$2.1M | -$4.9M |
| Proceeds from sale of available-for-sale securities | $6.8M | $3.5M | $3.5M |
| Maturities of available-for-sale securities | $34.8M | $18.4M | $52.7M |
| Investment in available-for-sale securities | -$114.1M | -$18.4M | -$27.1M |
| Purchases of intangible assets | $0 | -$300.0K | $0 |
| Investment in IPR&D | -$10.2M | $0 | $0 |
| Investment in convertible promissory note | -$2.0M | $0 | $0 |
| Proceeds from sale of divested entities | $23.5M | $73.4M | $0 |
| Payments on divestiture of Global Cooling | $0 | -$13.0M | $0 |
| Net cash (used in) provided by investing activities | -$71.5M | $58.3M | $17.8M |
| Payments on term loan | -$10.0M | -$5.0M | -$300.0K |
| Payments on equipment loans | $0 | -$1.6M | -$198.0K |
| Issuance of common stock | $0 | $0 | $10.2M |
| Proceeds from exercise of common stock options | $18.0K | $202.0K | $507.0K |
| Proceeds from financed insurance premium | $0 | $2.1M | $2.6M |
| Payments on financed insurance premium | -$975.0K | -$2.4M | -$2.4M |
| Other | $33.0K | -$74.0K | $64.0K |
| Net cash (used in) provided by financing activities | -$10.9M | -$6.8M | $10.6M |
| Net (decrease) increase in cash and cash equivalents | -$62.3M | $59.9M | $15.9M |
| Effects of currency translation on cash and cash equivalents | $0 | $0 | $35.0K |
| Assets acquired under operating leases | $0 | $5.8M | $880.0K |
| Assets acquired under finance leases | $0 | $0 | $1.7M |
| Purchase of property and equipment not yet paid | $0 | $107.0K | $359.0K |
| Unrealized loss (gain) on available-for-sale securities | $108.0K | -$18.0K | -$56.0K |
| Unrealized gain on currency translation | $0 | $0 | -$12.0K |
| Non-cash acquisition of PanTHERA | $5.3M | $0 | $0 |
| Cashless issuance of SciSafe earnout shares | $0 | $0 | $2.3M |
| Returned shares from settlement of Global Cooling escrow | $0 | $0 | -$5.1M |
| Cash interest paid | $762.0K | $1.6M | $1.9M |
No quarter-by-quarter statement was filed.
Corporate structure
BIOLIFE SOLUTIONS INC sits at the top of its group. 3 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of BIOLIFE SOLUTIONS INC
- GLAZER CAPITAL, LLC Filed SCHEDULE 13G on BIOLIFE SOLUTIONS INC, latest Sep 24, 2026
- T. Rowe Price Investment Management, Inc. Filed SCHEDULE 13G/A on BIOLIFE SOLUTIONS INC, latest Sep 8, 2026 (4 filings since Aug 14, 2025)
- Casdin Capital, LLC Filed SCHEDULE 13G on BIOLIFE SOLUTIONS INC, latest Jun 4, 2026 (8 filings since Oct 24, 2023)
- Invesco Filed SCHEDULE 13G/A on BIOLIFE SOLUTIONS INC, latest May 6, 2026 (3 filings since Nov 8, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on BIOLIFE SOLUTIONS INC, latest Mar 26, 2026 (4 filings since Feb 9, 2022)
- Goldman Sachs Filed SC 13G/A on BIOLIFE SOLUTIONS INC, latest Nov 1, 2024 (2 filings since Feb 2, 2024)
- INTEGRATED CORE STRATEGIES (US) LLC Filed SC 13G/A on BIOLIFE SOLUTIONS INC, latest Jan 24, 2024 (2 filings since Sep 26, 2023)
- BlackRock Filed SC 13G/A on BIOLIFE SOLUTIONS INC, latest Jan 23, 2024 (5 filings since Feb 1, 2022)
- MILLENNIUM MANAGEMENT LLC Filed SC 13G/A on BIOLIFE SOLUTIONS INC, latest Jan 11, 2023 (2 filings since Jun 22, 2022)
- Walter Villiger Filed SC 13D/A on BIOLIFE SOLUTIONS INC, latest Nov 1, 2021
- BIOLIFE SOLUTIONS INC Bothell, Washington, United States
- PanTHERA CryoSolutions, Inc. Subsidiary · Alberta, Canada
- Sexton Biotechnologies, Inc. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What BIOLIFE SOLUTIONS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $19.6M6 Dec 31, 2025 | $10.1M6 Dec 31, 2024 | +93.9% |
| Accumulated depreciation | $4.9M6 Dec 31, 2025 | $4.2M6 Dec 31, 2024 | +18.7% |
| Property and equipment, net | $14.7M6 Dec 31, 2025 | $6.0M6 Dec 31, 2024 | +146.3% |
| Operating-lease assets (leased space) | $7.5M6 Dec 31, 2025 | $10.6M6 Dec 31, 2024 | −29.3% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $33.0M6 Dec 31, 2025 | $91.5M6 Dec 31, 2024 | −63.9% |
| Marketable securities, current | $55.9M6 Dec 31, 2025 | $9.2M6 Dec 31, 2024 | +507.6% |
| Debt securities available for sale | $87.1M6 Dec 31, 2025 | $13.8M6 Dec 31, 2024 | +530.3% |
| Stakes in other companies (equity method) | $06 Dec 31, 2025 | $995.0K6 Dec 31, 2024 | −100.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $208.6M6 Dec 31, 2025 | $208.6M6 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $4.3M6 Dec 31, 2025 | $5.6M6 Dec 31, 2024 | −23.5% |
| Accumulated amortization | $6.4M6 Dec 31, 2025 | $5.2M6 Dec 31, 2024 | +23.5% |
| Finite-lived intangibles, net | $4.3M6 Dec 31, 2025 | $9.6M10 Dec 31, 2024 | −55.5% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $30.2M6 Dec 31, 2025 | $29.0M6 Dec 31, 2024 | +3.9% |
| Raw materials | $10.6M6 Dec 31, 2025 | $11.8M6 Dec 31, 2024 | −10.3% |
| Work in process | $6.4M6 Dec 31, 2025 | $4.1M6 Dec 31, 2024 | +56.1% |
| Finished goods | $13.2M6 Dec 31, 2025 | $13.2M6 Dec 31, 2024 | +0.5% |
Properties, in its own words
Our material office and manufacturing leases are detailed below:
Location · Square Feet · Principal Use · Lease Expiration
The rest of Item 2
Bothell, WA · 75,241 · Corporate headquarters, manufacturing, research and development, marketing, and administrative offices · July 2031
Woodinville, WA · 13,578 · Warehouse · February 2030
Manchester, CT · 524 · Research and development · August 2026
Indianapolis, IN · 10,890 · Manufacturing, research and development, and administrative offices · June 2027
Edmonton, AB · 200 · Research and development · March 2026
Ottawa, ON · 200 · Research and development · December 2026
We consider the facilities to be in a condition suitable for their current uses. Due to the increasing requirements of customers or regulatory agencies, we may need to acquire additional space or upgrade and enhance existing space. We believe that adequate facilities will be available upon the conclusion of our leases.
Item 2 of the 10-K filed Feb 26, 2026.5
Leadership
Who has led BIOLIFE SOLUTIONS INC, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerGreef Roderick De Nov 1, 2023 to now14
- Chief executive officerJohn G. Ph D. Baust Apr 18, 2006 to Apr 18, 200615
- PresidentDusty Tenney May 13, 2021 to May 13, 202116
- PresidentGreef Roderick De Nov 18, 2021 to now17
- Chief financial officerTroy Wichterman Nov 15, 2021 to now18
- Chief financial officerGreef Roderick De Mar 7, 2016 to Oct 27, 202119
- Chief financial officerDaphne L. Taylor Aug 23, 2011 to May 6, 201520
- Chief operating officerDusty Tenney May 13, 2021 to May 13, 202116
- Chief operating officerGreef Roderick De Jan 8, 2020 to Nov 30, 202221
- Chief operating officerJoe Annicchiarico Apr 16, 2014 to May 6, 201522
Board members and other officers (26)
- Chief Technology OfficerSean Werner Dec 6, 2024 to now23
- SVP, Global OperationsGeraint Phillips Jan 9, 2023 to Mar 12, 202424
- Chief Revenue OfficerGarrie Richardson Nov 1, 2023 to Sep 18, 202425
- VP, Global Human ResourcesSarah Aebersold Jan 7, 2021 to now26
- Vice President, Global SalesMarcus Schulz May 28, 2020 to Aug 29, 202327
- Vice President of SalesJames Mathers Jun 2, 2016 to Jun 1, 202028
- Vice President of OperationsKaren A. Foster Aug 26, 2016 to now29
- V.P. MarketingTodd Berard Feb 24, 2015 to now30
- VP of ManufacturingJoe Annicchiarico Aug 17, 2012 to Aug 17, 201231
- Chief Quality OfficerMark Sandifer Aug 17, 2012 to Aug 17, 201232
- Senior VPAby J. Mathew Aug 20, 2012 to now33
- Vice PresidentMatt Snyder Feb 9, 2007 to Mar 17, 201634
- Board memberAnthony Hunt Jan 10, 2025 to now35
- Board memberCatherine Coste Mar 20, 2025 to now36
- Board memberAmy Duross Apr 8, 2021 to now37
- Board memberRachel Ellingson Apr 8, 2021 to now38
- Board memberJoydeep Goswami Oct 7, 2021 to now39
- Board memberGmbh Taurus4757 Apr 5, 2017 to Jul 9, 201840
- Board memberFrederick Stewart Oct 2, 2013 to Mar 17, 201641
- Board memberJoseph C. Schick Nov 19, 2013 to Mar 12, 202442
- Board memberAndrew G. Hinson Feb 9, 2007 to Aug 18, 202143
- Board memberHoward S. Breslow Feb 9, 2007 to May 15, 201244
- Board memberGreef Roderick De Apr 18, 2006 to now45
- Board memberJohn G. Ph D. Baust Apr 18, 2006 to Apr 18, 200615
- Board memberThomas Girschweiler Apr 18, 2006 to Nov 30, 202046
- Board memberRaymond W. Cohen May 22, 2006 to Jul 14, 202147
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- CRYOMEDICAL SCIENCES INCOct 13, 1995 to Nov 14, 20023
Timeline
- Oct 6, 20268-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights49
- Sep 9, 20268-K Other events50
- Aug 6, 20268-K Results of operations51
- Aug 3, 20268-K Regulation FD disclosure52
- Jul 22, 20268-K Entered a material agreement; Regulation FD disclosure53
- Jun 3, 20268-K Regulation FD disclosure54
- May 7, 20268-K Results of operations55
- Mar 2, 20268-K Regulation FD disclosure56
- Feb 26, 20268-K Results of operations57
- Jan 12, 20268-K Results of operations58
- Jan 9, 20268-K Executive or director change59
- Nov 17, 20258-K Regulation FD disclosure60
- Nov 1, 2023New chief executive Greef Roderick De becomes CEO14
- Apr 18, 2006New chief executive John G. Ph D. Baust becomes CEO15
- Mar 25, 1998Founded BIOLIFE SOLUTIONS INC is founded2
Calendar
Coming up
- Around Nov 5, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.
When it reported results
- Aug 6, 2026Reported quarterly or annual results51
- May 7, 2026Reported quarterly or annual results55
- Feb 26, 2026Reported quarterly or annual results57
- Jan 12, 2026Reported quarterly or annual results58
- Nov 6, 2025Reported quarterly or annual results61
- Aug 7, 2025Reported quarterly or annual results62
- May 8, 2025Reported quarterly or annual results63
- Nov 12, 2024Reported quarterly or annual results64
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
826 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 57 major events, 652 insider forms, 32 large holders, 1 private raises, 62 other. The latest 20:
- Oct 9, 2026EFFECT EDGAR
- Oct 9, 2026EFFECT EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 8, 20264 EDGAR
- Oct 6, 202625-NSE EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026S-8 POS EDGAR
- Oct 6, 2026POS AM EDGAR
- Oct 6, 2026POS AM EDGAR
- Oct 6, 20268-K EDGAR
The 826 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
509 open-market trades by officers, directors and large owners since October 2021: 7 buys and 502 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 21, 2026 | Casdin Partners Master Fund, L.P.10% owner | Sale | 650,000 | $23.70 | $15.4M | Form 4 |
| May 20, 2026 | Casdin Partners Master Fund, L.P.10% owner | Sale | 250,000 | $23.70 | $5.9M | Form 4 |
| May 19, 2026 | Casdin Partners Master Fund, L.P.10% owner | Sale | 300,000 | $22.65 | $6.8M | Form 4 |
| Mar 23, 2026 | Foster Karen A.Chief Quality and Operations | Sale | 2,577 | $19.17 | $49.4K | Form 4 |
| Mar 9, 2026 | Foster Karen A.Chief Quality and Operations | Sale | 500 | $20.00 | $10.0K | Form 4 |
| Mar 5, 2026 | Foster Karen A.Chief Quality and Operations | Sale | 96,923 | $20.15 | $2.0M | Form 4 |
| Mar 3, 2026 | Werner SeanChief Technology Officer | Sale | 111 | $20.74 | $2.3K | Form 4 |
| Mar 3, 2026 | Foster Karen A.Chief Quality and Operations | Sale | 418 | $20.74 | $8.7K | Form 4 |
| Mar 3, 2026 | Mathew Aby J.EVP & Chief Scientific Officer | Sale | 529 | $20.74 | $11.0K | Form 4 |
| Mar 3, 2026 | Wichterman TroyChief Financial Officer | Sale | 588 | $20.74 | $12.2K | Form 4 |
| Mar 3, 2026 | Aebersold SarahChief Human Resources Officer | Sale | 219 | $20.74 | $4.5K | Form 4 |
| Mar 3, 2026 | Berard ToddChief Marketing Officer | Sale | 353 | $20.74 | $7.3K | Form 4 |
| Jan 6, 2026 | Wichterman TroyChief Financial Officer | Sale | 990 | $25.59 | $25.3K | Form 4 |
| Jan 6, 2026 | Foster Karen A.Chief Quality and Operations | Sale | 335 | $25.59 | $8.6K | Form 4 |
| Jan 6, 2026 | Aebersold SarahChief Human Resources Officer | Sale | 241 | $25.59 | $6.2K | Form 4 |
| Jan 6, 2026 | Mathew Aby J.EVP & Chief Scientific Officer | Sale | 405 | $25.59 | $10.4K | Form 4 |
| Jan 6, 2026 | Berard ToddChief Marketing Officer | Sale | 344 | $25.59 | $8.8K | Form 4 |
| Dec 15, 2025 | Aebersold SarahChief Human Resources Officer | Sale | 713 | $24.46 | $17.4K | Form 4 |
| Dec 15, 2025 | DuRoss AmyDirector | Sale | 2,000 | $24.60 | $49.2K | Form 4 |
| Dec 9, 2025 | Mathew Aby J.EVP & Chief Scientific Officer | Sale | 631 | $25.13 | $15.9K | Form 4 |
All 509 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- GLAZER CAPITAL, LLCSCHEDULE 13G, 1 filing Sep 24, 202665
- T. Rowe Price Investment Management, Inc.SCHEDULE 13G/A, 4 filings Aug 14, 2025 to Sep 8, 202666
- Casdin Capital, LLCSCHEDULE 13G, 8 filings Oct 24, 2023 to Jun 4, 202667
- InvescoSCHEDULE 13G/A, 3 filings Nov 8, 2024 to May 6, 202668
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 9, 2022 to Mar 26, 202669
- Goldman SachsSC 13G/A, 2 filings Feb 2, 2024 to Nov 1, 202470
- INTEGRATED CORE STRATEGIES (US) LLCSC 13G/A, 2 filings Sep 26, 2023 to Jan 24, 202471
- BlackRockSC 13G/A, 5 filings Feb 1, 2022 to Jan 23, 202472
- MILLENNIUM MANAGEMENT LLCSC 13G/A, 2 filings Jun 22, 2022 to Jan 11, 202373
- Walter VilligerSC 13D/A, 1 filing Nov 1, 202174
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2024 | Roderick de Greef | 64 | $744.5K | $7.0M75 |
| 2024 | Troy Wichterman | 40 | $472.0K | $2.6M75 |
| 2024 | Aby J. Mathew | $435.0K | $1.7M75 | |
| 2024 | Karen Foster | 65 | $430.0K | $1.5M75 |
| 2024 | Garrie Richardson - Former Chief Revenue Officer | $317.5K | $1.4M75 | |
| 2024 | Todd Berard - Chief Commercial Officer | $336.4K | $1.1M75 | |
| 2023 | Chief Executive Officer and | $198.9K | $5.3M75 | |
| 2023 | Chief Financial Officer | $472.0K | $1.7M75 | |
| 2023 | Executive VicePresident and | $435.0K | $1.3M75 | |
| 2023 | Chief Quality and Operations | $382.0K | $1.1M75 | |
| 2022 | Chairman of the Board | $450.0K | $2.4M75 | |
| 2022 | Chief Financial Officer | $375.0K | $1.8M75 | |
| 2022 | Chief Scientific Officer | $419.8K | $1.7M75 | |
| 2022 | Officer | $356.5K | $1.3M75 |
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $10.4M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2023 | $10.4M | $10.4M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Members of Congress who traded it
2 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Dec 12, 2022 | Christopher L. Jacobs, House | Sale | $1,001 - $15,000 | Report | |
| Nov 8, 2022 | Christopher L. Jacobs, House | Buy | $1,001 - $15,000 | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How BIOLIFE SOLUTIONS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBIOLIFE SOLUTIONS INC1
- CIK0000834365
- Employer ID (EIN)94-30768665
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address3303 Monte Villa Parkway, Suite 310, Bothell, WA 980211
- Phone42540114001
- Shares outstanding48,906,704 as of Jul 30, 202612
- Public float$845.0M as of Jun 30, 20255
- AuditorGRANT THORNTON LLP, Bellevue, Washington PCAOB ID 248; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceMay 15, 19951
- Filings1,735 in all: 4 (1,064), 8-K (226), 10-Q (66), 3 (32), 10QSB (28), 144 (27), 10-K (18), 4/A (18)1
All 59 form types
UPLOAD (18), CORRESP (17), DEF 14A (17), SC 13D/A (17), SC 13G/A (17), NT 10-K (14), SC 13G (12), 8-K/A (9), EFFECT (9), 10KSB (8), 424B3 (7), DEFA14A (7), S-1/A (7), SC 13D (7), 10-K/A (6), S-8 (6), SCHEDULE 13D/A (6), SCHEDULE 13G/A (6), NT 10-Q (5), S-3 (5), 425 (4), 10KSB40 (3), 10QSB/A (3), POS AM (3), S-3/A (3), S-8 POS (3), SCHEDULE 13G (3), 10-K405 (2), 10-Q/A (2), 10KSB/A (2), 424B5 (2), 5 (2), CT ORDER (2), DEF 14C (2), PRE 14A (2), PRE 14C (2), REGDEX (2), 10-KT (1), 10KSB40/A (1), 25-NSE (1), 424B4 (1), 8-A12B (1), ARS (1), CERTNAS (1), D (1), DEFM14A (1), DEFR14A (1), S-1 (1), S-1MEF (1), S-3ASR (1), S-3MEF (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Jul 8, 2025
Latest 8-K (8-K) Oct 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, par value $0.001 per share | BLFS | Nasdaq |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks BIOLIFE SOLUTIONS INC names in Item 1A of its 10-K filed Feb 26, 2026: 38 risks under these headings, as written.5
- Risks related to our business and operations
- If our products or the products of our competitors do not perform as expected or the reliability of the technology on which our products are based is questioned, we could experience lost revenue, delayed or reduced market acceptance of our products, increased costs, and damage to our reputation.
- We operate in a highly competitive industry and if we cannot compete effectively, our business, financial condition and operating results could be materially and adversely affected.
- Despite our increasingly diversified customer base, we depend on a limited number of customers and products in a limited number of market sectors. If we lose any of these large customers or if there are disruptions in the sales of these products, our net product revenue and operating results could decline significantly.
- We expect our operating results to fluctuate significantly from period to period.
- If intangible assets and goodwill become impaired, we may have to take significant charges against earnings.
- Our success will depend on our ability to attract and retain key personnel.
- Our business may be subject to product liability claims or product recalls, which could be expensive and could result in a diversion of management’s attention.
- Difficulties in manufacturing could have an adverse effect upon our expenses and our product revenues.
- We are dependent on our suppliers and third-party manufacturers, including single-source and sole-source suppliers, and disruptions in our supply chain could adversely affect our ability to manufacture and deliver products.
- While we are not currently subject to FDA or other regulatory approvals, if our products become subject to regulatory requirements, the manufacture and sale of our products may be delayed or prevented, or we may become subject to increased expenses.
- We and our customers are subject to various international governmental regulations. Compliance with, or changes in, such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.
The other 27 risks
- Healthcare reform measures could adversely affect our business and financial results.
- Insurance coverage is increasingly difficult to obtain or maintain.
- We are and may become the subject of various claims, litigation or investigations which could have a material adverse effect on our business, financial condition, or results of operations or the price of our common stock.
- Our business and operations could be negatively affected by securities litigation or stockholder activism, which could impact the trading price and volatility of our common stock and may constrain capital deployment opportunities and adversely impact our ability to expand our business.
- Risks related to our acquisition and divestiture activities
- Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies.
- Our recent divestitures expose us to ongoing risks and uncertainties, one or more of which could have a material adverse effect on our business, financial condition, results of operations, cash flows, and/or stock price.
- Risks related to our intellectual property, cyber security, and artificial intelligence
- Our proprietary rights may not adequately protect our technologies and products.
- Expiration of our patents may subject us to increased competition and reduce our opportunity to generate product revenue.
- We may not be able to protect our intellectual property rights throughout the world.
- We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights to, or use of, our technology.
- Even if we are granted a patent, in certain circumstances we may be unable to protect our rights to, or use of, our technology.
- We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
- Our inability to protect our information systems and networks and the proprietary and confidential information in our possession from continually evolving cybersecurity risks or other technological risks, including as a result of breaches of our associated third parties' information technology systems, could materially adversely impact our business, financial condition and results of operations, in addition to our reputation and relationships with our employees, customers, suppliers and business partners.
- The development, deployment and use of AI technologies present new risks and challenges that could adversely impact our business.
- Risks related to our common stock
- Our stock price and volume may be volatile, and purchasers of our securities could incur substantial losses.
- A significant percentage of our outstanding common stock is held by one stockholder, and this stockholder therefore has significant influence on us and our corporate actions.
- We have not paid dividends on our common stock in the past and do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.
- Certain provisions in our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
- Our Amended and Restated Bylaws designate the Court of Chancery of the State of Delaware and U.S. federal district courts as the exclusive forums for certain types of actions and proceedings that may be initiated by our stockholders, which limits our stockholders’ ability to choose the judicial forum for disputes with us or our directors, officers, or other employees.
- Risks related to accounting matters
- We have identified material weaknesses in our internal control over financial reporting, and if our remediation of such material weaknesses is not effective, or if we are unable to develop and maintain an effective system of internal control over financial reporting or disclosure controls and procedures, we may not be able to accurately and timely report financial results or prevent fraud, and our ability to meet our reporting obligations and the trading price of our common stock could be negatively affected.
- Changes in tax laws and regulations could adversely affect our financial condition and results of operations.
- Our ability to use NOL and tax credit carryforwards and certain built-in losses to reduce future tax payments is limited by provisions of the Internal Revenue Code, and it is possible that certain transactions or a combination of certain transactions may result in material additional limitations on our ability to use our NOL and tax credit carryforwards.
- Risks related to disruptive events
- Natural disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could disrupt the supply, delivery or demand of products, which could negatively affect our operations and performance.
- Tariffs and other trade policies could have a substantial impact on our business.
- Unfavorable currency exchange rate fluctuations may impact our operating margins, or may cause us to raise prices for our products and services, which could result in reduced sales.
- Public health crises have adversely affected, and could in the future adversely affect, our business, financial condition. results of operations and cash flows.
- Global climate change and related legal and regulatory developments could negatively affect our business, financial condition and results of operations.
Legal proceedings
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARDusty Tenney, President
- 17SEC EDGARGreef Roderick De, President
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30SEC EDGARTodd Berard, V.P. Marketing
- 31
- 32SEC EDGARMark Sandifer, Chief Quality Officer
- 33SEC EDGARAby J. Mathew, Senior VP
- 34SEC EDGARMatt Snyder, Vice President
- 35SEC EDGARAnthony Hunt, Board member
- 36SEC EDGARCatherine Coste, Board member
- 37SEC EDGARAmy Duross, Board member
- 38SEC EDGARRachel Ellingson, Board member
- 39SEC EDGARJoydeep Goswami, Board member
- 40SEC EDGARGmbh Taurus4757, Board member
- 41SEC EDGARFrederick Stewart, Board member
- 42SEC EDGARJoseph C. Schick, Board member
- 43SEC EDGARAndrew G. Hinson, Board member
- 44SEC EDGARHoward S. Breslow, Board member
- 45SEC EDGARGreef Roderick De, Board member
- 46SEC EDGARThomas Girschweiler, Board member
- 47SEC EDGARRaymond W. Cohen, Board member
- 48
- 49
- 50SEC EDGAROther events
- 51SEC EDGARResults of operations
- 52SEC EDGARRegulation FD disclosure
- 53
- 54SEC EDGARRegulation FD disclosure
- 55SEC EDGARResults of operations
- 56SEC EDGARRegulation FD disclosure
- 57SEC EDGARResults of operations
- 58SEC EDGARResults of operations
- 59SEC EDGARExecutive or director change
- 60SEC EDGARRegulation FD disclosure
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75